rs2233580 — PAX4 Arg192His

PAX4 Arg192His — Impaired Beta-Cell Transcription Factor in East Asians

The pancreatic beta cell is a specialist — it exists for one purpose: sensing blood glucose and releasing exactly the right amount of insulin. Building and maintaining that specialization requires a master transcription factor called PAX4 (paired box gene 4¹¹ paired box gene 4
PAX4 controls beta-cell development and differentiation during embryogenesis and throughout life). When PAX4 function is compromised, the beta cell loses its identity, its capacity to produce insulin, and its ability to suppress glucagon — the hormone that keeps glucose rising between meals.

The rs2233580 variant encodes a single amino acid change in the PAX4 protein: arginine to histidine at position 192 (Arg192His). This is an East and Southeast Asian–specific variant, virtually absent in European and African populations. Among East Asians it reaches a minor allele frequency of roughly 9–10%, making it one of the most clinically significant population-specific diabetes risk variants known.

The Mechanism

PAX4 normally acts as a transcriptional repressor²² transcriptional repressor
a protein that binds to DNA and turns off neighboring genes. It binds the promoters of the insulin gene and the glucagon gene, keeping glucagon expression suppressed in beta cells while supporting insulin transcription. The Arg192His change sits in the homeodomain DNA-binding region of the protein and measurably weakens this repressor function. Luciferase reporter assays show that PAX4 R192H has significantly reduced ability to repress both the insulin and glucagon promoters compared to wild-type PAX4.

The downstream consequences are visible at the cellular level. In EndoC-βH1 beta cells, PAX4 knockdown impairs insulin secretion and reduces total insulin content. In CRISPR-derived hiPSC islet models³³ CRISPR-derived hiPSC islet models
human induced pluripotent stem cells differentiated into islet-like structures in the lab, deletion or mutation of PAX4 causes de-repression of alpha-cell gene expression (particularly glucagon), an increase in polyhormonal "confused" cells, and reduced beta-cell identity markers. These phenotypes were fully rescued by CRISPR-mediated gene correction — confirming that Arg192His is the causal variant, not a passenger mutation.

The Evidence

The first genome-wide significant association came from a Chinese exome-chip study: 7,189 T2D cases and 10,813 controls in Hong Kong and Guangzhou, combined p = 3.74×10⁻¹⁵⁴⁴ 7,189 T2D cases and 10,813 controls in Hong Kong and Guangzhou, combined p = 3.74×10⁻¹⁵
Guo et al. Exome-chip association analysis reveals an Asian-specific missense variant in PAX4 associated with type 2 diabetes in Chinese individuals. Diabetologia, 2017.

A large study of early-onset T2D in Chinese found that 21.4% of 2,886 patients with early-onset T2D carried at least one Arg192His allele⁵⁵ 21.4% of 2,886 patients with early-onset T2D carried at least one Arg192His allele
Ma et al. Missense variants in PAX4 are associated with early-onset diabetes in Chinese. Diabetes Therapy, 2021. The combined odds ratio was 1.88 (95% CI 1.37–2.60). Carriers showed higher HbA1c, lower 2-hour C-peptide levels, and a dose-dependent shift toward younger age of diagnosis.

Functional confirmation came from a 2023 Nature Communications study using isogenic hiPSC lines carrying the Arg192His allele: participants heterozygous or homozygous for p.His192 showed decreased acute insulin response to glucose and reduced HOMA-B beta-cell function⁶⁶ participants heterozygous or homozygous for p.His192 showed decreased acute insulin response to glucose and reduced HOMA-B beta-cell function
Hastoy et al. PAX4 loss of function increases diabetes risk by altering human pancreatic endocrine cell development. Nature Communications, 2023.

A Singapore cohort study among East Asians confirmed the association with younger age of T2D onset and reduced C-peptide⁷⁷ association with younger age of T2D onset and reduced C-peptide
Ang et al. PAX4 R192H is associated with younger onset of type 2 diabetes in East Asians in Singapore. Diabetes Research and Clinical Practice, 2019.

One pharmacogenomic study found that patients with the CC genotype (Arg/Arg) achieved significantly better fasting glucose control on sulfonylurea monotherapy than CT or TT carriers⁸⁸ CC genotype (Arg/Arg) achieved significantly better fasting glucose control on sulfonylurea monotherapy than CT or TT carriers
Chen et al. Effects of TCF7L2 rs7903146 and PAX4 rs2233580 on hypoglycemic agent therapeutic efficacy. Heliyon, 2024.

Practical Actions

Carriers of one or two T alleles have measurably reduced beta-cell function. The core implication is impaired glucose-stimulated insulin secretion. Dietary patterns that minimize postprandial glucose spikes directly reduce the demand placed on already-compromised beta cells. Monitoring for early metabolic changes (fasting glucose, HbA1c, fasting insulin) is warranted, especially in East Asian individuals who carry the variant — since the risk is population-concentrated, it is most clinically relevant for this group.

Carriers may have reduced benefit from sulfonylureas (which act by stimulating beta-cell insulin release) compared to biguanides (which improve insulin sensitivity), though this pharmacogenomic finding is preliminary and should be discussed with a prescribing physician.

Interactions

PAX4 rs2233580 (R192H) and rs3824004 (R192S) affect the same amino acid position 192 in the PAX4 homeodomain. Among East Asians, compound heterozygous carriers of one R192H and one R192S allele show dramatically higher T2D risk (OR ~3.23 vs OR ~1.78 for single-variant carriers), as documented in Ma et al. 2021 (PMID 33216280). This compound effect is worth flagging in genetic counseling for East Asian patients with early-onset T2D.

Both PAX4 rs2233580 and TCF7L2 rs7903146 affect beta-cell insulin secretion through distinct mechanisms (transcription factor function vs. Wnt/incretin pathway), and their combination in a patient informs differential response to first-line oral diabetes medications.